Patients with chronic hepatitis B virus infection can achieve sustained viral suppression with long-term tenofovir disoproxil fumarate treatment without developing resistance, shows a 7-year study.
Switching to tenofovir may stave further kidney and bone impairment in patients with hepatitis B virus-related chronic hepatitis taking adefovir-based therapy, retrospective study findings suggest.
The combination of age and baseline hepatitis B s-antigen level can help predict hepatitis B virus relapse in patients who achieve hepatitis B e-antigen loss or seroconversion following nucleos(t)ide analogue (NA) treatment, researchers report.
US researchers have identified a survival benefit of postoperative combination chemotherapy and radiation treatment in patients with non-small-cell lung cancer who have microscopically positive surgical margins, regardless of pathological stage.
Phase III trial findings suggest that carrying out stereotactic radiosurgery before chemotherapy does not improve overall survival for non-small-cell lung cancer patients with asymptomatic brain metastases compared with chemotherapy alone.
Monitoring plasma cell-free DNA levels of epidermal growth factor receptor mutations may indicate prognosis for patients with lung adenocarcinoma after EGFR–tyrosine kinase inhibitor therapy, research suggests.
Preliminary findings suggest that nonmyeloablative haematopoietic stem cell transplantation may arrest, or even reverse, the progress of disease among patients with relapsing–remitting multiple sclerosis.
LUME-Lung 1 trial patients’ reports of symptoms and health-related quality of life support the use of second-line nintedanib for the treatment of advanced non-small-cell lung cancer.
A third of non-small-cell lung cancers show low- to high-level amplification of the MET gene, according to a German study, with no significant difference in frequency across different types of cancer and genetic backgrounds.
Individuals with advanced non-small-cell lung cancer who have rare or complex epidermal growth factor receptor mutations have inferior outcomes in response to EGFR–tyrosine kinase inhibitor treatment compared with those with common mutations, research indicates.